You are Trying to View a Premium Article

Daily News You Can't Find Anywhere Else

Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company


Industry Segment: Pharmaceutical & Biotech | Word Count: 702 Words

GALWAY, IRELAND--December 2, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical major Novartis International AG (NYSE:NVS) (Basel, Switzerland) is betting big on heart drug prospect inclisiran with a 8.8 billion euro ($9.7 billion) takeover of The Medicines Company (NASDAQ: MDCO) (New Jersey).

Within this article: Details takeover, drugs involved, rivals and market opportunity

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now! All Fields Required...

Subscription Type: Pricing Help?

  • Pay-Per-Article - $3.95
  • Annual Subscription - $235.00
  • Annual Subscription with Archive - $395.00